Stereotactic Ablative Radiation Therapy for Abiraterone-Resistant, Oligoprogressive Metastatic Prostate Cancer

Castration-Resistant Prostate Cancer Clinical Trial

Official title:

Stereotactic Ablative Radiotherapy for Oligoprogressive Metastatic Castration-Resistant Prostate Cancer During Abiraterone Therapy

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04838899
• Other study ID #: #351
• Status: Recruiting
• Phase: N/A
• Start date: July 16, 2016
• Est. completion date: December 31, 2026

Study information

• Verified date: April 2024
• Source: Sunnybrook Health Sciences Centre
• Contact: Urban Emmenegger, MD
• Phone: +416-480-4928
• Email: urban.emmenegger[@]sunnybrook.ca
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

There is increasing worldwide interest in exploring stereotactic ablative body radiotherapy (SABR) for treating metastases in men with prostate cancer, including for the treatment of oligoprogressive metastases. The latter applies to a situation whereby patients with widespread metastases undergoing systemic therapy present with a solitary or a few metastatic tumors that progress, while all other metastases are stable or responding. The usual practice would be to change systemic therapy at this point, but another approach is to locally ablate the "rogue" metastases and continue the same systemic therapy. SABR used in this scenario may delay the need to switch to another line of systemic therapy and improve progression-free survival while patients stay on the same systemic therapy.

Description:

There is increasing worldwide interest in exploring the use of SABR for metastatic, treatment-naive prostate cancer, eg for delaying the need to start androgen deprivation therapy (ADT), and ultimately to improve patient outcome.

Another potential use of SABR for metastatic prostate cancer is in the setting of oligoprogression. In patients undergoing systemic therapy, oligoprogression describes the clinical situation where a solitary or a few metastatic tumors progress, while all other metastases are stable or responding. The usual practice would be to change systemic therapy at this point, but another approach is to locally ablate the "rogue" metastases and continue the same systemic therapy. There is limited clinical evidence for such an approach, eg in renal cell and non-small cell lung cancer.

While there is a lack of published evidence of such an approach in metastatic castration-resistant prostate cancer (mCPRC), SABR for oligoprogressive mCRPC in men undergoing abiraterone therapy may delay the need to switch to another line of systemic therapy, such as chemotherapy, and thereby to improve progression-free survival while patients stay on the same systemic therapy.

mCRPC is a unique solid tumor to study the oligoprogressive setting for several reasons. First, there still remains a limited number of proven systemic agents in the CRPC setting. Second, serum prostate specific antigen (PSA) is an excellent biomarker of prostate cancer activity, which is easy to collect and analyze to monitor treatment response and disease progression. Third, because of the low α/β value of prostate cancer, hypofractionated SABR may be a very effective and convenient way to eradicate areas of known disease.

The primary objective of this phase I study is to determine the incidence of acute and late toxicities associated with delivering SABR to all progressive metastatic sites in patients with metastatic CRPC who present with oligoprogression while on abiraterone. We also aim to obtain preliminary efficacy data of this novel approach. Patients will remain on abiraterone after SABR to measure the added progression-free survival.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: December 31, 2026
• Est. primary completion date: December 31, 2025
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• ECOG performance status 0-1.

• Histologic confirmation of prostate adenocarcinoma.

• Documentation of metastatic, castration-resistant prostate cancer.

• Patient being treated with abiraterone.

• Evidence of oligoprogression (according to RECIST [V1.1] and/or Prostate Cancer Working Group criteria [PCWG3], as applicable), applying any of the following: (i) = 5 metastatic lesions progressing on conventional imaging (= 3 progressing metastases in any one organ system) while all other metastases are controlled or responding; (ii) PSA progression only, but in the setting of oligometastases (= 5 metastatic lesions seen on imaging, with = 3 metastases in any one organ system); in this setting, all metastases will be irradiated.

• All metastases of interest amenable to SABR.

Exclusion Criteria:

• Patients presenting with unequivocal clinical progression, defined as one of the following: (i) cancer pain requiring the initiation of opioid therapy; (ii) immediate need for cytotoxic chemotherapy as per treating physician's discretion; or (iii) deterioration of performance status to grade = 3 according to ECOG.

• Evidence of spinal cord compression.

• Prior malignancy within the past 5 years, excluding non-melanoma skin cancer, and in-situ cancer.

Related Conditions & MeSH terms

• Castration-Resistant Prostate Cancer
• Oligoprogressive
• Prostatic Neoplasms

Intervention

Radiation:
• Stereotactic Body Radiation Therapy (SABR)
SABR to oligoprogressive metastases while continuing abiraterone therapy

Locations

Country	Name	City	State
Canada	Odette Cancer Centre	Toronto	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
Sunnybrook Health Sciences Centre

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	SABR-related toxicities	Incidence of acute and late toxicities (including radiation induced bone fractures) after comprehensive SABR to all progressing metastases seen on conventional imaging.	12 months
Primary	Progression-free survival	Time to clinical (i.e., radiological and/or symptomatic) progression following SABR.	24 months
Secondary	Biochemical progression-free survival	Time to PSA progression	24 months
Secondary	Time to changing systemic therapy	Time to starting subsequent line of systemic therapy	24 months
Secondary	Radiographic local control rate of the SABR-treated areas	Monitoring lack of progression of oligoprogressive sites of disease	24 months
Secondary	Radiographic distant progression-free survival	Time to metastatic progression outside of SABR-treated areas	24 months
Secondary	Overall survival	Time to death from prostate cancer or other cause	36 months
Secondary	Quality of Life (QoL) assessment	QoL assessment using EORTC QLQ-C30 at baseline, plus 1, 3, 6, 9 and 12 months after SABR	12 months